GC Wealth Management RIA’s Cue Biopharma CUE Stock Holding History

GC Wealth Management RIA’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-154,388	Closed	-$1.06M	–	504
2026 Q1	$1.06M	Hold	154,388	–	–	0.04%	231
2025 Q4	$1.41M	Buy	154,388 +40,000	+35%	+$735K	0.05%	197
2025 Q3	$2.47M	Buy	114,388 +3,333	+3%	+$78.2K	0.08%	187
2025 Q2	$2.27M	Buy	+111,055	New	+$2.37M	0.19%	122

Other funds holding CUE

Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GC Wealth Management RIA's CUE Position: Q2 2026 in Review

GC Wealth Management RIA sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 154,388 shares — an estimated $1.06M sold.

GC Wealth Management RIA first reported a position in CUE in Q2 2025 and held it in 4 quarters. The position peaked at $2.47M in Q3 2025. 3 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

GC Wealth Management RIA reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
GC Wealth Management RIA sold 154,388 Cue Biopharma shares in Q2 2026, an estimated $1.06M.
GC Wealth Management RIA first reported a position in Cue Biopharma in Q2 2025 and held it in 4 quarters.
GC Wealth Management RIA's Cue Biopharma position peaked at $2.47M in Q3 2025.
3 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on GC Wealth Management RIA's 13F filing for Q2 2026, filed 16 Jul 2026.